Not really understanding what all the confusion is about. I think the announcement is pretty simple,
1. They are currently investigating 1102 to understand its mode of action and for further indication.
2. The study is being done via blood samples retained in the Phase 2 study.
3. From the study they will file for extra patents.
4. They expect to present these findings at a scientific conference this year given 1-3.
Where others have failed will Atl1102 succeed ?, page-257
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.005(3.85%) |
Mkt cap ! $121.7M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 14.0¢ | 13.0¢ | $115.9K | 858.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 550387 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 399821 | 7 |
View Market Depth
| Last trade - 12.37pm 14/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |